Literature DB >> 31336144

TLR3 preconditioning induces anti-inflammatory and anti-ictogenic effects in mice mediated by the IRF3/IFN-β axis.

C Kostoula1, T Shaker2, M Cerovic1, I Craparotta3, S Marchini3, E Butti4, R Pascente1, V Iori1, C Garlanda5, E Aronica6, G Martino4, T Ravizza1, L Carmant2, A Vezzani7.   

Abstract

Activation of Toll-like receptor 3 (TLR3) was previously shown to contribute to the generation of epileptic seizures in rodents by evoking a proinflammatory response in the forebrain. This suggests that TLR3 blockade may provide therapeutic effects in epilepsy. We report that brain activation of TLR3 using the synthetic receptor ligand Poly I:C may also result in remarkable dose- and time-dependent inhibitory effects on acute seizures in mice without inducing inflammation. These inhibitory effects are associated with reduced neuronal excitability in the hippocampus as shown by a decrease in the population spike amplitude of CA1 pyramidal neurons following Schaffer collaterals stimulation. TLR3 activation which results in seizure inhibition does not evoke NF-kB-dependent inflammatory molecules or morphological activation of glia, however, it induces the alternative interferon (IFN) regulatory factor (IRF)-3/IFN-β signaling pathway. IFN-β reproduced the inhibitory effects of Poly I:C on neuronal excitability in hippocampal slices. Seizure inhibition attained with activation the TLR3-IRF3/IFN-β axis should be carefully considered when TLR3 are targeted for therapeutic purposes. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hippocampus; Inflammation; Interferon; Poly I:C; Seizures; Toll-like receptors; Viral encephalitis

Year:  2019        PMID: 31336144     DOI: 10.1016/j.bbi.2019.07.021

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  8 in total

Review 1.  Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries.

Authors:  Gagandeep Singh; Samuel A Angwafor; Alfred K Njamnshi; Henry Fraimow; Josemir W Sander
Journal:  Nat Rev Neurol       Date:  2020-05-19       Impact factor: 42.937

Review 2.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

Review 3.  Potential role of IFN-α in COVID-19 patients and its underlying treatment options.

Authors:  Lei Yang; Jianhui Wang; Pei Hui; Timur O Yarovinsky; Saiaditya Badeti; Kien Pham; Chen Liu
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-05       Impact factor: 4.813

Review 4.  Reactive Glia Inflammatory Signaling Pathways and Epilepsy.

Authors:  Pascual Sanz; Maria Adelaida Garcia-Gimeno
Journal:  Int J Mol Sci       Date:  2020-06-08       Impact factor: 5.923

5.  The innate immune system and neurogenesis as modulating mechanisms of electroconvulsive therapy in pre-clinical studies.

Authors:  Juliette Giacobbe; Carmine M Pariante; Alessandra Borsini
Journal:  J Psychopharmacol       Date:  2020-07-10       Impact factor: 4.153

Review 6.  Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.

Authors:  Vince Kornél Grolmusz; Anikó Bozsik; János Papp; Attila Patócs
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

7.  Ginsenoside Rh2 Ameliorates Neuropathic Pain by inhibition of the miRNA21-TLR8-mitogen-activated protein kinase axis.

Authors:  Yuan-Yuan Fu; Jian-Ke Cen; Hao-Lin Song; Si-Yuan Song; Zhi-Jun Zhang; Huan-Jun Lu
Journal:  Mol Pain       Date:  2022-04       Impact factor: 3.370

Review 8.  SARS-CoV-2 infection-induced immune responses: Friends or foes?

Authors:  Keying Li; Zhenhua Hao; Xiaohui Zhao; Jiying Du; Yanlin Zhou
Journal:  Scand J Immunol       Date:  2020-06-17       Impact factor: 3.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.